Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
International Breast Cancer Study Group · Vall d'Hebron Institute of Oncology · +16 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,784
total citations
- FWCI
- 91.94
- Percentile
- 100%
- References
- 27
Citations per year
Authors
227- JCJavier CortésCorresponding
International Breast Cancer Study Group, Vall d'Hebron Institute of Oncology
- DWDavid W. Cescon
Princess Margaret Cancer Centre
- HSHope S. Rugo
University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center
- ZNZbigniew Nowecki
The Maria Sklodowska-Curie National Research Institute of Oncology
- SISeock‐Ah Im
Seoul National University Hospital
Topics & keywords
Topics
Keywords
- Medicine
- Carboplatin
- Gemcitabine
- Internal medicine
- Pembrolizumab
- Triple-negative breast cancer
- Breast cancer
- Oncology
No related works found for this paper.